Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 7,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Active, not recruiting Phase 2 Interventional

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel

NCT05751668
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
Interventions
Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration, Quality-of-life assessment, Placebo Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
33
States / cities
Irvine, California • Orange, California • Clearwater, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

NCT04596150
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
Interventions
CX-2009, CX-072
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
La Jolla, California • Los Angeles, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 31, 2026, 11:12 PM EDT
Completed No phase listed Observational

Emulation of the PALOMA-2 Trial

NCT07178743
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Initiation of palbociclib plus letrozole, Initiation of letrozole
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
6,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

NCT03874325
View directory record Official record
Conditions
Breast Cancer, Hormone Receptor Positive Tumor
Interventions
Durvalumab, Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 MG
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 31, 2026, 11:12 PM EDT
Recruiting Phase 2 Interventional

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

NCT04434040
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
Interventions
Atezolizumab, Sacituzumab govitecan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • New Lenox, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms

NCT01641068
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor, Cognitive Side Effects of Cancer Therapy, Malignant Female Reproductive System Neoplasm
Interventions
Cognitive Intervention, Educational Intervention, Functional Magnetic Resonance Imaging, Memory Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

NCT00193076
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Carboplatin, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

NCT00530868
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast, Breast Neoplasm
Interventions
Letrozole (Femara), Letrozole; Avastin
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

NCT00671918
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Lymphoseek
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Alexander City, Alabama • Birmingham, Alabama • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 1 Interventional Results available

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

NCT04315233
View directory record Official record
Conditions
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Interventions
Ribociclib, Belinostat
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Salt Lake City, Utah • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

Trial to Evaluate an Educational Video Series for Women in Breast Cancer Treatment

NCT07434817
View directory record Official record
Conditions
Breast Cancer Females, Newly Diagnosed Breast Cancer
Interventions
Sexual Health Educational Video Series, Standard Care (in control arm)
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

NCT02219789
View directory record Official record
Conditions
Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Alisertib, Fulvestrant, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

NCT00244959
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, adjuvant therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

NCT00996762
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 11:12 PM EDT
Completed No phase listed Observational

Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer

NCT00898703
View directory record Official record
Conditions
Breast Cancer
Interventions
flow cytometry, immunoenzyme technique, laboratory biomarker analysis
Other
Lead sponsor
University of Arizona
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Risk Education and Assessment for Cancer Heredity

NCT01346761
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Genetic Predisposition
Interventions
Telephone Genetic Counseling, In-Person Genetic Counseling
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 74 Years · Female only
Enrollment
1,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02213042
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Mobile, Alabama • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

NCT04132817
View directory record Official record
Conditions
Breast Cancer
Interventions
Nivolumab, Ipilimumab, Nab-paclitaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 31, 2026, 11:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

NCT04711824
View directory record Official record
Conditions
Breast Cancer, Brain Metastases, Adult
Interventions
Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy
Drug · Radiation
Lead sponsor
Colette Shen
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT03337724
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 31, 2026, 11:12 PM EDT
Suspended Phase 1 Interventional

DNX-2440 for Resectable Colorectal Liver Metastasis

NCT04714983
View directory record Official record
Conditions
Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer, Gastric Cancer, Periampullary Cancer, Melanoma, Renal Cell Cancer, Sarcoma, Squamous Cell Carcinoma, Gastrointestinal Stromal Tumors
Interventions
DNX-2440
Biological
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

NCT04353973
View directory record Official record
Conditions
Cancer
Interventions
Pre-Test Intervention, Standard of Care, Post-Test Intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

NCT00934856
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Pertuzumab, Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional

Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure

NCT03879629
View directory record Official record
Conditions
Breast Cancer
Interventions
Carvedilol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 31, 2026, 11:12 PM EDT